Gastrointestinal Cancer Market Landscape 2025: Forecast Data and Growth Strategy Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gastrointestinal Cancer Market Through 2025?
In recent times, there has been a swift expansion in the market size for gastrointestinal cancer. The market, which is projected to grow from $24.09 billion in 2024 to $27.05 billion in 2025, predicts a compound annual growth rate (CAGR) of 12.3%. The significant growth witnessed in the historical phase is a result of the increasing cases of gastrointestinal cancers coupled with the rise in tobacco and alcohol intake, a surge in the elderly population, unhealthy eating behaviors, and advances in oncology diagnostic and therapeutic procedures.

What's the Projected Size of the Global Gastrointestinal Cancer Market by 2029?
The market for gastrointestinal cancer is projected to experience swift expansion in the upcoming years. It's forecasted to swell to $42.45 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. This imminent growth within the forecasted duration can be attributed to numerous factors including the escalating adoption of therapies driven by biomarkers, heightened awareness about preventive screening at early stages, development in the healare infrastructure, government-led initiatives towards cancer treatment, and an increasing inclination towards minimally invasive procedures. The major trends anticipated during this forecast period are advancements in diagnostic tool technology, innovation in targeted therapy methodologies, progress in the field of immunotherapy, the burgeoning use of artificial intelligence in cancer management, and continued research and development in precision oncology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Top Growth Drivers in the Gastrointestinal Cancer Industry: What's Accelerating the Market?
The growth of the gastrointestinal cancer market is anticipated to be propelled by an increased embrace of targeted therapies. These therapies, aimed at obstructing the growth of cancer cells by acting on distinct molecular targets, reduce the damage to normal, healthy cells. Designed to work on exact molecular pathways or genetic abnormalities that fuel a disease, particularly cancer, targeted therapies differ from traditional treatments such as chemotherapy, which affect both healthy and diseased cells. Targeted treatments for gastrointestinal (GI) cancer act on unique genes or proteins that regulate tumor growth, allowing for an accurate and potent treatment. This results in improved outcomes with lesser side effects as compared to traditional chemotherapy. For example, as per the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, and Citeline, a US-based supplier of drugs and devices, as of July 2023, there were 247 gene therapies in Phase II at the end of the first quarter (Q1) 2023. This number elevated by 5% to reach 260 by the second quarter's (Q2) conclusion. Thus, the growing acceptance of targeted therapies is propelling the expansion of the gastrointestinal cancer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Trends Will Shape the Gastrointestinal Cancer Market Through 2029 and Beyond?
Leading businesses in the gastrointestinal cancer market are working on creating superior solutions like monoclonal antibody treatment with the aim of enhancing survival rates of patients while reducing the side effects associated with the treatment. This kind of treatment employs antibodies produced in a lab setting that accurately recognize and bind to the cancer cells, aiding the immune system in identifying and destroying them. In September 2024, Astellas Pharma Inc., a pharmaceutical firm based in Japan, introduced VYLOY (zolbetuximab) used in tandem with fluoropyrimidine- and platinum-based chemotherapy. This was approved by the European Commission and is the initial line of treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma with tumors that express claudin 18.2 (CLDN18.2). The endorsement has set VYLOY as the sole therapy in the European Union aiming at CLDN18.2, a biomarker present in roughly 38% of such patients, as per the positive results from the SPOTLIGHT and GLOW studies.

What Are the Main Segments in the Gastrointestinal Cancer Market?
The gastrointestinal cancer market covered in this report is segmented -

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types
2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics
3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:
1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer
2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors
3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors
4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors
5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer
6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Which Top Companies are Driving Growth in the Gastrointestinal Cancer Market?
Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

Which Regions Will Dominate the Gastrointestinal Cancer Market Through 2029?
North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24546

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.